Table 5.
Association between genotypes (rs9789675, rs9789398, and rs1004478) and the risk of PH in COPD
| SNP | Model | Genotype | Control | Case | Without adjustment
|
With adjustment
|
||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P-valuea | OR (95% CI) | P-valueb | |||||
| rs9789675 | Codominant | GG | 248 (70.2%) | 115 (79.3%) | 1.00 | 0.084 | 1.00 | 0.110 |
| GA | 98 (27.8%) | 29 (20%) | 0.64 (0.40–1.02) | 0.64 (0.40–1.04) | ||||
| AA | 7 (2%) | 1 (0.7%) | 0.31 (0.04–2.53) | 0.35 (0.04–2.90) | ||||
| Dominant | GG | 248 (70.2%) | 115 (79.3%) | 1.00 | 0.036* | 1.00 | 0.045 | |
| GA–AA | 105 (29.8%) | 30 (20.7%) | 0.62 (0.39–0.98) | 0.6 (0.39–1.00) | ||||
| Recessive | GG–GA | 346 (98%) | 144 (99.3%) | 1.00 | 0.260 | 1.00 | 0.330 | |
| AA | 7 (2%) | 1 (0.7%) | 0.34 (0.04–2.82) | 0.39 (0.05–3.21) | ||||
| Overdominant | GG–AA | 255 (72.2%) | 116 (80%) | 1.00 | 0.066 | 1.00 | 0.076 | |
| GA | 98 (27.8%) | 29 (20%) | 0.65 (0.41–1.04) | 0.66 (0.41–1.05) | ||||
| Log additive | – | – | – | 0.62 (0.40–0.96) | 0.027* | 0.64 (0.41–0.99) | 0.037 | |
| rs9789398 | Codominant | TT | 237 (70.1%) | 114 (79.7%) | 1.00 | 0.082 | 1.00 | 0.100 |
| TC | 96 (28.4%) | 28 (19.6%) | 0.61 (0.38–0.98) | 0.61 (0.38–0.99) | ||||
| CC | 5 (1.5%) | 1 (0.7%) | 0.42 (0.05–3.60) | 0.47 (0.05–4.17) | ||||
| Dominant | TT | 237 (70.1%) | 114 (79.7%) | 1.00 | 0.027* | 1.00 | 0.034* | |
| TC–CC | 101 (29.9%) | 1 (1.7%) | 0.60 (0.37–0.95) | 0.60 (0.38–0.97) | ||||
| Recessive | TT–TC | 333 (98.5%) | 115 (80.4%) | 1.00 | 0.46 | 1.00 | 0.540 | |
| CC | 5 (1.5%) | 28 (19.6%) | 0.47 (0.05–4.05) | 0.53 (0.06–4.65) | ||||
| Overdominant | TT–CC | 242 (71.6%) | 1.00 | 0.04* | 1.00 | 0.045* | ||
| TC | 96 (28.4%) | 0.61 (0.38–0.99) | 0.62 (0.38–1.00) | |||||
| Log additive | – | – | – | 0.61 (0.39–0.95) | 0.026* | 0.62 (0.40–0.98) | 0.034* | |
| rs1004478 | Codominant | CC | 140 (39.4%) | 73 (49.7%) | 1.00 | 0.048* | 1.00 | 0.055 |
| CG | 175 (49.3%) | 55 (37.4%) | 0.60 (0.40–0.91) | 0.60 (0.40–0.92) | ||||
| GG | 40 (11.3%) | 19 (12.9%) | 0.91 (0.49–1.69) | 0.88 (0.47–1.64) | ||||
| Dominant | CC | 140 (39.4%) | 73 (49.7%) | 1.00 | 0.036* | 1.00 | 0.036* | |
| CG–GG | 215 (60.6%) | 74 (50.3%) | 0.66 (0.45–0.97) | 0.66 (0.44–0.92) | ||||
| Recessive | CC–CG | 312 (88.7%) | 128 (87.1%) | 1.00 | 0.600 | 1.00 | 0.690 | |
| GG | 40 (11.3%) | 19 (12.9%) | 1.17 (0.65–2.10) | 1.13 (0.62–2.03) | ||||
| Overdominant | CC–GG | 180 (50.7%) | 92 (62.6%) | 1.00 | 0.015* | 1.00 | 0.018* | |
| CG | 175 (49.3%) | 55 (37.4%) | 0.61 (0.41–0.91) | 0.62 (0.42–0.93) | ||||
| Log additive | – | – | – | 0.82 (0.61–1.10) | 0.190 | 0.82 (0.61–1.10) | 0.170 | |
Notes:
*
P<0.05 indicates statistical significance.
a
P-values were calculated by two-sided χ2 tests or Fisher’s exact tests for each genotype distribution.
b
P-values were calculated by unconditional logistic regression adjusted for age, sex, and smoking status.
Abbreviations: CI, confidence interval; OR, odds ratio; PH, pulmonary hypertension; SNP, single nucleotide polymorphism.